Cannabis Goes Global: Tilray and Organigram Lead the Charge

Two Canadian Giants Chart the Course for International Cannabis Dominance

The first week of April 2026 has delivered a pair of blockbuster developments that together paint a vivid picture of where the global cannabis industry is headed. Tilray Brands reported record-breaking third-quarter results with $207 million in net revenue, while Organigram secured shareholder approval for its landmark €250 million acquisition of Germany's Sanity Group. These are not isolated wins. They are coordinated signals that the North American cannabis playbook is going international.

Tilray's Record Quarter by the Numbers

Tilray Brands delivered its strongest financial performance to date for the third quarter of fiscal 2026, ending February 28. Net revenue reached $206.7 million, an 11 percent increase over the $185.8 million reported in the same period last year. This was not just growth; it was record growth across multiple business segments.

Gross profit climbed 6 percent year-over-year to a record $55 million, while adjusted EBITDA improved 19 percent to $10.7 million. The company also reported a net loss of $25.2 million, but context matters here. That figure represents a staggering 97 percent improvement compared to the prior year's loss, suggesting Tilray is on a credible path toward profitability.

The cannabis segment was particularly impressive, with net revenue jumping 19 percent to $64.8 million. International cannabis revenue surged 73 percent, driven primarily by growing demand in Germany and other European markets. Canadian adult-use and medical cannabis combined for an 8 percent increase, demonstrating that Tilray is not just chasing international growth at the expense of its home market.

Organigram's European Bet Gets the Green Light

While Tilray was posting record numbers, Organigram was securing the final piece of a puzzle that could reshape European cannabis for years to come. On March 30, 2026, Organigram shareholders approved the proposed acquisition of Sanity Group GmbH, one of Germany's leading medical cannabis companies.

The deal, valued at up to €250 million, is structured in two parts. Upfront consideration of €113.4 million consists of €80 million in cash and €33.4 million in Organigram shares. An additional €113.8 million in potential earnout payments, with the first €20 million in cash and up to €93.8 million in shares, is tied to Sanity Group's financial performance over the twelve months following closing.

The acquisition is expected to close in April 2026, pending customary conditions, with financing coming from a combination of cash on hand, a new credit facility, and an expected C$65.2 million equity investment from British American Tobacco, a strategic partner that underscores the level of institutional interest flowing into cannabis.

Why Germany Is the Prize

Both Tilray and Organigram have identified Germany as the linchpin of their European strategies, and the reasoning is straightforward. Germany legalized recreational cannabis for adults in April 2024, creating the largest legal cannabis market in Europe overnight. With a population of over 83 million and a robust healthcare system that already covers medical cannabis prescriptions, Germany represents an addressable market that dwarfs any individual U.S. state.

For Tilray, Germany has been a focus for several years, and the company already operates cultivation and distribution infrastructure in the country. The 73 percent surge in international cannabis revenue reported in Q3 reflects the early returns on this investment.

Organigram's approach through the Sanity Group acquisition is more aggressive. Rather than building from scratch, Organigram is buying one of Germany's most established cannabis brands, along with its distribution networks, regulatory licenses, and market relationships. The deal also provides expansion pathways into Poland, the United Kingdom, Switzerland, and Czechia, markets where Sanity Group already has operations or regulatory groundwork in place.

What This Means for the Global Cannabis Landscape

The Tilray and Organigram developments are not happening in a vacuum. They reflect a broader trend of North American cannabis companies pivoting toward international markets as domestic growth faces headwinds from regulatory uncertainty, market saturation in mature states, and persistent federal prohibition in the United States.

The global legal cannabis market is projected to exceed $47 billion in 2026, with Europe representing the fastest-growing regional segment. Companies that establish early footholds in markets like Germany, the UK, and Australia stand to benefit from first-mover advantages that could prove durable as these markets scale.

For investors, the message is clear. The next phase of cannabis industry growth will not be defined by which company opens the most dispensaries in California or Illinois. It will be defined by which companies can successfully navigate the complex regulatory environments of international markets while maintaining the operational discipline needed to turn revenue growth into actual profitability.

The Road Ahead

Tilray's path to profitability appears increasingly credible, with the 97 percent reduction in net loss and consistent revenue growth suggesting the company's diversified strategy across cannabis, beverages, and wellness products is beginning to deliver. CEO Irwin Simon has repeatedly emphasized that Tilray's multi-category approach is designed to create resilience against the regulatory volatility that plagues pure-play cannabis companies.

Organigram faces a different set of challenges. Integrating a European company across multiple jurisdictions while managing cultural and regulatory differences is no small task. The earnout structure of the Sanity Group deal provides some protection against overpayment, but execution risk remains significant.

What both companies share is a conviction that the future of cannabis is global, and that the window to establish dominant international positions is narrowing. For an industry that has spent the better part of a decade focused on state-by-state U.S. expansion, this pivot toward global ambition marks a significant evolution in strategic thinking.